Previous Article | Next Article 
Journal of Virology, November 1999, p. 9576-9583, Vol. 73, No. 11
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Pathogenesis of Experimental Rhesus
Cytomegalovirus Infection
Kristen M.
Lockridge,
Getachew
Sequar,
Shan Shan
Zhou,
Yujuan
Yue,
Carol P.
Mandell, and
Peter A.
Barry*
Center for Comparative Medicine, Department
of Medical Pathology, University of California
Davis, Davis,
California
Received 25 May 1999/Accepted 28 July 1999
 |
ABSTRACT |
Human cytomegalovirus (HCMV) establishes and maintains a lifelong
persistence following infection in an immunocompetent host. The
determinants of a stable virus-host relationship are poorly defined. A
nonhuman primate model for HCMV was used to investigate virological and
host parameters of infection in a healthy host. Juvenile rhesus
macaques (Macaca mulatta) were inoculated with rhesus
cytomegalovirus (RhCMV), either orally or intravenously (i.v.), and
longitudinally necropsied. None of the animals displayed clinical signs
of disease, although hematologic abnormalities were observed
intermittently in i.v. inoculated animals. RhCMV DNA was detected
transiently in the plasma of all animals at 1 to 2 weeks postinfection
(wpi) and in multiple tissues beginning at 2 to 4 wpi. Splenic tissue
was the only organ positive for RhCMV DNA in all animals. The location
of splenic cells expressing RhCMV immediate-early protein 1 (IE1) in
i.v. inoculated animals changed following inoculation. At 4 to 5 wpi,
most IE1-positive cells were perifollicular, and at 25 wpi, the
majority were located within the red pulp. All animals developed
anti-RhCMV immunoglobulin M (IgM) antibodies within 1 to 2 wpi and IgG
antibodies within 2 to 4 wpi against a limited number of viral
proteins. Host reactivity to RhCMV proteins increased in titer (total
and neutralizing) and avidity with time. These results demonstrate that
while antiviral immune responses were able to protect from disease,
they were insufficient to eliminate reservoirs of persistent viral gene expression.
 |
INTRODUCTION |
Human cytomegalovirus (HCMV)
infection does not generally result in clinical outcomes in
immunocompetent hosts. Host antiviral responses rapidly restrict viral
replication, such that most HCMV infections in healthy individuals are
asymptomatic. While cellular and humoral antiviral immune responses can
limit viral infection (4), HCMV can establish a lifelong
persistence in a healthy host. Persistence is characterized by the
presence of latent viral genomes that periodically reactivate to
produce infectious virus (32). HCMV infects multiple cell
types throughout the host, and recurrent virus can be shed from
multiple sites (4, 29, 34). Rates of virus shedding can be
as high as 39% in some study populations of healthy individuals
(12, 14-16, 38, 41). Recurrent viral excretion is
asymptomatic in most healthy hosts, although reactivated virus in
immunosuppressed individuals presents serious clinical concern
(4).
The mechanisms of HCMV persistence are not resolved. Results from in
vitro and in vivo studies suggest that the virus utilizes a variety of
strategies to maintain itself in a host despite vigorous cellular and
humoral antiviral immune responses. Persistence strategies appear to
include (i) broad cell tropism of the virus (36), (ii)
differential patterns of gene expression in different cell types
(17-19, 23, 24, 39, 40, 45, 49), (iii) novel patterns of
gene expression (23, 24) and distinct genomic structures
during latency (9), and (iv) expression of viral gene
products that can modulate host immune responses (1, 2, 13, 20,
21, 28, 33, 37, 48). A major limitation to a better understanding
of the determinants of a persistent infection is restricted knowledge
concerning the early events of viral infection in vivo.
A nonhuman primate model of HCMV was used to investigate early stages
of viral infection. Primate CMVs are closely related in terms of
genetics (3, 8, 11, 25, 43), epidemiology (47),
and the patterns of infection in immunocompetent and immunodeficient hosts (6, 27, 44, 47). In the study described here, juvenile rhesus macaques were experimentally inoculated with rhesus CMV (RhCMV)
either intravenously (i.v.) or orally (p.o.), and virological and host
parameters of infection were longitudinally analyzed.
 |
MATERIALS AND METHODS |
Animals and inoculations.
Healthy, RhCMV-seronegative,
juvenile rhesus macaques (n = 9, 4 to 6 months old)
were used for these studies. Animals were screened by Western blot
analysis for seronegativity to RhCMV prior to inoculations. Animals
were inoculated i.v. with 0.4 ml of virus stock that contained either
106 (n = 3) or 104
(n = 3) 50% tissue culture infectious doses of RhCMV
strain 68-1 per ml. Three animals were inoculated p.o. with
106 50% tissue culture infectious doses of virus by
placing the inoculum (0.4 ml) at the back of the tongue in anesthetized
animals. The 68-1 strain of RhCMV has been demonstrated to be
pathogenic in fetal macaques (44). Inoculated animals were
monitored daily. Longitudinal blood samples were analyzed by complete
blood counts and fluorescence-activated cell sorter analysis of
CD3+-, CD4+-, and CD8+-cell
populations (described below). Scheduled necropsies were performed at 2 (n = 1), 4 to 5 (n = 3), 8 (n = 1), 13 to 14 (n = 2), and 25 (n = 2) weeks postinfection (wpi). The inoculation and
sampling schedule is detailed in Table 2.
Hematologic evaluation and CD4/CD8 T-lymphocyte
immunophenotyping.
Complete blood counts were performed by the
Clinical Laboratory at the California Regional Primate Research Center
with EDTA-anticoagulated blood. Fifty microliters of whole blood was
incubated for 15 to 30 min at room temperature with monoclonal
antibodies specific for CD3 (10 µl, fluorescein isothiocyanate
conjugated) (catalogue no. 35694X; Pharmingen, San Diego, Calif.), CD4
(5 µl, phycoerythrin conjugated) (catalogue no. 703430; Ortho
Diagnostics, Raritan, N.J.), and CD8 (5 µl, peridinin chlorophyll
protein [PerCP] conjugated) (catalogue no. 347314, Becton Dickinson,
Mountain View, Calif.). Samples were processed (Q-Prep; Coulter,
Hialeah, Fla.) and analyzed by three-color flow cytometry with a
FACScan (Becton Dickinson). Fluorescence-activated cell sorter analysis
was performed by the Optical Biology Laboratory, Department of Medical
Pathology, University of California, Davis.
Necropsy and histology.
Animals were culled at defined time
points during the study period (see Table 2). Complete necropsy
examinations were performed. Tissues were utilized for histologic
examination and nucleic acid purification. Tissues were fixed in 10%
formalin for a period of time not exceeding 5 days prior to paraffin
embedding (46).
PCR.
DNA was purified from necropsy tissues by using a lysis
buffer containing 1% sodium dodecyl sulfate, 20 mM Tris (pH 7.5), 250 mM NaCl, 20 mM EDTA, and 0.5 mg of proteinase K per ml. Tissues were
incubated in lysis buffer overnight at 63°C, and fresh lysis buffer
was added until the tissues were completely digested. After phenol-chloroform extraction and precipitation with ethanol, DNA concentrations were determined spectrophotometrically. Viral DNA was
purified from 200 µl of plasma by using the QIAmp blood kit (Qiagen,
Valencia, Calif.); DNA was eluted in a volume of 50 µl of water.
Nested PCR (40 cycles of 1 min at 94°C, 1 min at 55°C, and 1 min at
72°C) was performed with 1 µg of DNA as the template and primers to
exon 5 of immediate-early protein 2 (IE2) (8). For the first
round of PCR, primers PAB196 (5' GCCAATGCATCCTCTGGATGTATTGTGA 3') and PAB249 (5' TGCTTGGGGAATCTCTGCAC 3') were used.
For the second nested round of PCR, 5 µl of the first-round product
of PCR was amplified by using primers PAB201 (5'
CCCTTCCTGACTACTAATGTAC 3') and PAB248 (5'
TTGGGGAATCTCTGCACAAG 3'). A volume of 10 µl of plasma
DNA eluate was used as the template for PCR.
Immunohistochemistry.
The expression and distribution of
RhCMV IE1 were determined by immunohistochemistry. Briefly, slides were
deparaffinized for 20 min at 65°C and rehydrated (46).
They were then incubated in 3% hydrogen peroxide-distilled water for
10 min, followed by incubation in 10 mM sodium citrate for 4 h at
90°C. Slides were cooled to 25°C for 20 to 30 min and then washed
three times in phosphate-buffered saline (PBS). To reduce nonspecific
binding, tissue sections were treated for 30 min with Protein Block
Serum-Free (Dako, Carpinteria, Calif.) at 25°C. After being washed
with PBS, slides were incubated with primary antibody (1:3,200 in
PBS-0.1% Tween 20 [PBS-T]) overnight at 4°C. For these studies, a
rabbit polyclonal antiserum was generated against a bacterially
synthesized protein corresponding to exon 4 of the RhCMV IE1 gene
(8) (proteins were synthesized by Casey Morrow, University
of Alabama at Birmingham). Following three washes in PBS-T, secondary
antibody (biotinylated goat anti-rabbit, 1:800; Vector, Carpinteria,
Calif.) was added and left for 1 h at 25°C. The slides were
washed again three times in PBS-T, and avidin-biotin
complex-peroxidase (ABC) (Vector) was added, followed by
diaminobenzidine (DAB) (Vector) as a substrate for 1 h at 25°C.
Tissues were further processed according to published protocols
(46).
For double-immunolabeling experiments, tissues were incubated overnight
at 4°C with antisera against both IE1 and markers specific for B
cells (CD20; 1:500 dilution) (Dako; catalogue no. M0755), macrophages
(HAMS56; 1:400) (Dako; M0634), dendritic and endothelial cells
(p55/fascin; 1:5,000) (Dako; M3567), or plasma cells (immunoglobulin G
[IgG]; 1:200) (Accurate Chemical Co., Westbury, N.Y.; YNGM01GGFCP).
The antibody against fascin recognizes both endothelial and dendritic
cells within the spleen and other lymphoid organs (35).
After being washed three times in PBS-T, tissues were incubated with
biotinylated secondary antibody (1:800) for 1 h at 25°C and then
incubated with ABC, followed by DAB staining (as described above).
After optimal color development, slides were incubated in distilled
water to stop additional color development and then in 3% hydrogen
peroxide (10 min at 25°C) to inactivate the conjugated peroxidase.
After being washed in PBS-T, tissues were incubated in biotinylated
anti-rabbit antibody (1:800), ABC, and VIP peroxidase substrate
(Vector) to yield a purple product in IE1-expressing cells. Because the
anti-T (CD3; 1:400) (Dako; A0452) antibody was rabbit polyclonal
antiserum, double-labeling experiments for IE1 and CD3 were not
feasible. Four-micrometer serial tissue sections were individually
analyzed for IE1 or CD3 expression and compared.
Western blot analysis.
Western blot analysis for anti-RhCMV
IgG was performed by previously published protocols (47)
with a 1:100 dilution of plasma and RhCMV-infected rhesus skin
fibroblasts as the antigen.
Neutralization assays.
Assays to measure neutralizing
antibody titers were performed as described by Andreoni et al.
(5) with modifications. Primary rhesus skin fibroblasts were
plated at a density of 2 × 104 cells per well of a
96-well plate on the day prior to the neutralization assay.
Heat-inactivated (30 min, 56°C) plasma was twofold serially diluted
in Dulbecco modified Eagle medium-10% calf serum in a final volume of
24 µl. A stock of RhCMV of known titer was diluted to give a final
titer of 100 infectious virus particles per 50 µl; 168 µl of
diluted virus was added to each plasma dilution. Samples were vortexed
and incubated at 37°C in a water bath for 2 h, and then 50 µl
of plasma-virus was added in triplicate to cells and incubated at
37°C in a CO2 incubator for 3.5 h. Virus was
removed, and cells were fed normal growth medium. Sixteen hours later,
the cells were fixed in methanol-acetone (1:1) for 20 min, washed four
times in PBS, and then incubated in 1% bovine serum albumin (BSA) in
PBS-T (BSA-PBS-T) for 2 h at 25°C. The blocking solution was
removed, and anti-IE1 rabbit polyclonal antibody (diluted 1:3,200 in
BSA-PBS-T) was added and left for 2 h at 25°C. Plates were
washed three times in PBS-T and then incubated with biotinylated goat
anti-monkey IgG (1:800) (Sigma, St. Louis, Mo.) for 1 h. After
being washed, the plates were incubated in ABC Elite (Vector) for 30 min, followed by addition of DAB chromogenic substrate. The number of
stained nuclei in each well was counted and compared with those in
wells incubated with virus and medium alone. The neutralization titer
was calculated as the inverse of the plasma dilution resulting in a
50% reduction of IE1-positive cells per well.
ELISA antiviral antibody titers.
Anti-RhCMV IgM and IgG
antibodies were quantified by enzyme-linked immunosorbent assay
(ELISA), using a modification of published protocols (31).
Briefly, primary rhesus skin fibroblasts were infected with RhCMV and
harvested in NaOH-glycine buffer when the cells exhibited 100%
cytopathic effect. After sonication of the lysate, the protein
concentration was determined, and aliquoted extracts (500 µg/ml) were
stored at
20°C. Individual wells of a 96-well plate were coated
with 1 µg of protein in carbonate buffer (pH 9.6) (31)
overnight at 4°C. After being washed three times in PBS-T, wells were
incubated with blocking solution (BSA-PBS) for 2 h at 25°C.
Plasma samples, including a pool of RhCMV-seronegative plasma, were
serially diluted in BSA-PBS-T. The wells were washed, and diluted
plasma samples were loaded in duplicate at 100 µl/well. Wells were
incubated with plasma for 2 h at 25°C, washed three times, and
incubated with 100 µl of goat anti-monkey IgG peroxidase-conjugated antibody (diluted in BSA-PBS-T) (Kirkegaard and Perry Laboratories, Gaithersburg, Md.) for 1 h at 25°C. Peroxidase-conjugated goat anti-monkey IgM antibody (Kirkegaard and Perry) (diluted in BSA-PBS-T) was used for the IgM ELISA. The tetramethylbenzidine liquid substrate system (Sigma) was used as a substrate (30 min at 25°C), and the reaction was stopped with 0.5 M H2SO4 (50 µl/well). Absorbency at 450 nm (A450) was
recorded within 1 h.
Antibody avidity.
Antibody avidity was determined by
published protocols (10) with modifications. Briefly, the
first plasma sample with detectable anti-RhCMV IgG and the terminal
plasma sample were diluted 1:100 in BSA-PBS-T. Following incubation
and removal of diluted plasma, the wells were incubated for 15 min with
increasing concentrations (0, 1.0, 1.5, 2.0, 2.5, and 3.0 M) of sodium
thiocyanate (NaSCN) diluted in PBS. The wells were subsequently washed
and processed as described above. The avidity index was calculated as
the molar concentration of NaSCN required to reduce the
A450 by 50% compared to that observed in the
absence of NaSCN.
 |
RESULTS |
Hematologic analysis and T-lymphocyte immunophenotyping.
All
animals inoculated with RhCMV remained clinically healthy during the
study. None of the p.o. inoculated animals demonstrated any
significant hematologic change from preinoculation values. However, all
six monkeys inoculated i.v. exhibited hematologic abnormalities
in association with viral infection. Four animals (29850, 29840, 29762, and 29848) developed leukocytosis at 2, 4, 5, and 8 wpi, respectively,
compared to reference ranges; leukocytosis was transient, except for
animal 29850, which exhibited persistent leukocytosis 2 to 8 wpi.
Monocytosis was periodically observed in five of six animals.
Monocytosis was particularly noteworthy in animal 29840 at 4 wpi; it
coincided with a marked neutrophilia (14,452/µl) and
lymphocytosis (22,684 lymphocytes/µl). Transient neutrophilia
was also observed in animals 29762 and 29850 (at 5 and 3 wpi,
respectively). Erythrocyte and platelet numbers remained within the
reference ranges for the study period for all animals except 29840. At
4 wpi, this animal exhibited a marked thrombocytopenia (16 × 105/µl).
Viral infection was associated with acute changes in CD4/CD8 ratios in
all i.v. inoculated animals. No changes were observed in p.o.
inoculated animals. For i.v. inoculations, an initial decrease in
CD4/CD8 ratios was seen at 2 wpi, followed by a gradual return to
preinoculation values beginning at 3 wpi. The most prominent changes in
ratios were observed for animals 29840 and 29848, with CD4/CD8 ratios
dropping from 2.1 and 2.3, respectively, to 0.7. Decreases in CD4/CD8
ratios were due to increases in both CD8+ CD3+
T lymphocytes and CD8+ CD3
natural killer
(NK) cells. No consistent changes were observed for absolute
CD4+-cell numbers.
Immunologic analysis.
All animals except 29831 (inoculated
p.o.) developed detectable antiviral IgM antibodies by 2 wpi (Table
1). Peak titers were observed at 1 to 2 wpi and ranged from 640 to >5,120. Titers of IgM antibodies decreased
rapidly and were generally undetectable by 4 to 8 wpi; low levels of
IgM antibodies were noted in animal 29850 at 13 and 25 wpi.
Anti-RhCMV IgG antibodies were first detected at 2 wpi in five animals
(one inoculated p.o. and four inoculated i.v.) (Table 1) and at 4 wpi
in three animals; there were no detectable IgG titers for animal 29831 (p.o.) at the 2 wpi necropsy time point (100-fold minimal antibody
dilution). Antiviral IgG antibodies reached maximal titers between 10 and 25 wpi for the two animals (29848 and 29850) studied for 25 weeks
(Table 1). Recent studies have suggested that antibody avidity is a
qualitative measure of protection (10). Antibody avidity was
determined for each animal (except 29831) by using the first
IgG-positive plasma sample and the terminal plasma sample. For each
animal with two time points analyzed, antibody avidity increased with
time. Increases were observed at early time intervals (animal 29840 at
2 to 4 wpi), and avidity continued to increase until at least 25 wpi (animals 29848 and 29850) (Table 1). It should be noted that anti-RhCMV
titers for animals 29848 and 29850 at 25 wpi were comparable to those
observed in seropositive adult macaques housed in outdoor breeding
corrals (data not shown). However, the avidity indices for animals
29848 and 29850 were at the lower end of the range observed in corral
animals (avidity index of 3.0 to 5.0) (data not shown), indicating that
the time frame for antibody maturation is greater than 6 months.
The kinetics of antiviral antibody development coincided with the
appearance of neutralizing antiviral antibodies. Microneutralization assays (5) were performed with longitudinal plasma samples from p.o. inoculated animals 30457 and 30460 and i.v. inoculated animals 29840, 29740, and 29848. Neutralizing antibody titers were
first detected at 2 wpi for animals 29740 and 29848 and at 4 wpi for
the other three animals examined (Table 1). Titers of neutralizing
antibodies increased until 13 weeks for animals 29740 and 29848.
Host immune responses were directed initially against a limited number
(one to seven) of viral proteins with approximate sizes of 49, 60, 65, 80, 86/87, and 105 kDa; representative examples are presented for
animals 30460 (inoculated p.o.) and 29850 (inoculated i.v.) in Fig.
1. The pattern of immune reactivity
became increasingly complex at later stages of infection, particularly
for animals 29848 (not shown) and 29850. The relative
intensities against some proteins (e.g., the 85/87-kDa protein)
appeared to increase during the course of observation, while others
(e.g., the 49-kDa protein) stabilized quickly. Other proteins,
particularly the 60-, 65-, and 80-kDa proteins, appeared
to decline in relative titer. The identities of reactive
proteins are not known, although antibodies to glycoprotein B were
detected at 2 to 3 wpi (10a).

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 1.
Western blot analysis of plasma from inoculated animals.
Longitudinal plasma samples from p.o. (30460) and i.v. (29840, 29740, and 29848) inoculated animals were evaluated by Western blotting for
reactivity to RhCMV antigens. The time points for each plasma sample
(wpi) are given below each lane. Molecular masses are shown at the
right and left.
|
|
Detection of RhCMV DNA in plasma.
RhCMV genomic DNA
was amplified from DNA purified from plasma by using primers to exon 5 of IE2 (8). RhCMV DNA was first detectable in plasma at
1 wpi for all animals except 30457 (Fig. 2). For animal 30457, RhCMV DNA was
detected initially in plasma at the 2 wpi time point. Four animals, one
inoculated p.o. (30457) and three inoculated i.v. (29762, 29848, and 29850), were PCR positive for RhCMV DNA in plasma at
more than one time point, although the amplified products were barely
visible by ethidium bromide staining after the 1 wpi time point (Fig.
2). No attempt was made to culture virus from plasma. Therefore, it is
not known if RhCMV DNA in plasma represented infectious virus.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 2.
PCR analysis of RhCMV DNA in inoculated animals.
Longitudinal plasma samples (top panels) and tissues obtained at
necropsy (bottom panels) from p.o. (left panels) and i.v. (right
panels; 29840, 29740, and 29848 only) inoculated (Inoc.) animals were
analyzed for RhCMV DNA. For plasma samples, wpi are shown (week 0 was not available for animals 29831 and 29762). Samples with a positive
signal (+) are indicated. Tissue samples analyzed were axillary LN
(lanes 1), bone marrow (lanes 2), pancreas (lanes 3), ileum (lanes 4),
inguinal LN (lanes 5), jejunum (lanes 6), kidney (lanes 7), lung 1 (lanes 8), lung 2 (lanes 9), submandibular gland (lanes 10), spleen
(lanes 11), thymus (lanes 12), tonsil (lanes 13), liver (lanes 14),
parotid gland (lanes 15), and esophagus (p.o. inoculated animals only)
and duodenum (i.v. inoculated animals only) (lanes 16). Lane P,
positive control tissue; lane M, molecular weight markers.
|
|
Histopathology.
The most significant histopathologic finding
was lymphofollicular hyperplasia in all animals, involving the
duodenum, jejunum, lymph nodes (LN), spleen, and tonsils (Table
2). Lymphoid hyperplasia ranged from mild
to marked or severe and was noted at both early and late time points;
hyperplasia was most prominent in animals 29740 (inoculated i.v.) and
30460 (inoculated p.o.) and was accompanied by germinal center
hyalinization. In addition, a neutrophilic splenitis occurred in two
p.o. inoculated animals (30457 and 30460) and all i.v. inoculated
animals and was characterized by prominent neutrophilic infiltrates in
the red pulp. Splenitis ranged from mild (animals 29848 and 29721) to
moderate (30457, 29840, and 29762) to marked (30460, 29740, and 29850).
Viral inclusions were not observed in any tissue.
Immunohistochemistry.
Immunohistochemical analysis for IE1
expression was performed with tissues that were positive for RhCMV
DNA (discussed below). IE1 expression was detected only in the spleens
of i.v. inoculated animals and was localized to the nucleus of splenic
cells (Fig. 3). The cellular location of
IE1-positive cells within the spleen changed during the course of
infection. At 4 to 5 wpi, most cells expressing IE1 were perifollicular
(Fig. 3A). Lower numbers of IE1-positive cells were seen within the
follicles and in the red pulp. To estimate the extent of viral
expression within the spleen, the number of IE1-positive follicles was
counted. A total of 86% (68 of 79) of the splenic follicles in animal
29840 and 14% (14 of 100) in animal 29721 contained cells staining for
IE1 in a representative section (data not shown). In contrast, the
majority of splenic cells expressing IE1 at 25 wpi (Fig. 3C) were
located within the red pulp. Only occasional IE1-positive cells were
present in perifollicular areas; no follicular germinal centers were
positive for IE1. For animal 29850, 14% of the perifollicular areas
(14 of 99) had cells expressing IE1; 2% of the perifollicular areas (2 of 93) in animal 29848 were positive for IE1 expression. The two
animals analyzed at 12 to 13 wpi (29740 and 29762) exhibited an
intermediate pattern, with IE1-positive cells in both perifollicular areas and the red pulp (Fig. 3B).

View larger version (146K):
[in this window]
[in a new window]
|
FIG. 3.
Immunohistochemical localization of RhCMV
IE1-expressing cells in the spleen. (A to C) Spleen sections from
animals 29840 (A), 29740 (B), and 29848 (C) were assayed for RhCMV
IE1 expression. IE1-positive cells are brown (DAB), and the cells are
counterstained with hematoxylin (blue). The location of a
representative follicle (f) is indicated. (D and E) Cells were double
labeled for IE1 expression and markers for endothelial cells (D) or
macrophages (E). (D) Endothelial cells are brown, and IE1-positive
cells are purple. (E) Macrophages are pink, and IE1-positive cells are
brown. Double-labeled cells are indicated by arrows. Many of the
IE1-expressing cells are not stained with either cell type marker.
|
|
Histologically, it appeared that multiple cell types supported viral
gene expression (Fig. 3A to C). Cells positive for RhCMV IE1
expression within the mantle zone of the follicle usually contained a
thin, flattened nucleus and cytoplasm, suggestive of endothelial or
fibroblast cells. Positive cells either within the follicle or in the
parenchyma of the red pulp had variable morphologies. Many of these
cells contained either a large round or a reniform nucleus (consistent
with that of a macrophage), while others were elliptical or irregular
in shape.
To further examine the cell tropism for RhCMV in the spleen, double
immunohistochemistry was performed with antibodies to RhCMV IE1 and
cell-specific markers for B, T, macrophage, endothelial and dendritic,
or plasma cells. The results demonstrated that IE1 was occasionally
colocalized to endothelial cells within both perifollicular areas (data
not shown) and the sinusoids of the red pulp (Fig. 3D) and to tissue
macrophages in the red pulp (Fig. 3E). However, most IE1-positive cells
did not costain for either the macrophage or endothelial cell marker;
representative IE1-positive cells not stained with either the
macrophage or endothelial cell marker are seen in Fig. 3D and E. In
addition, there was no evidence for expression of IE1 within the other
cell types examined (plasma, B, or dendritic) in any animal (data
not shown). Analysis of serial splenic sections for IE1 and the
CD3 T-cell marker also failed to conclusively identify IE1 expression
within this cell type.
Detection of RhCMV DNA in tissues.
The spleen was the only
tissue that was PCR positive in all nine animals (Fig. 2). For i.v.
inoculations, axillary LN were positive in five animals, inguinal LN
were positive in four, bone marrow was positive in three, and liver was
positive in two. Multiple tissues (pancreas, ileum, kidney, lung,
tonsil, thymus, submandibular gland, and mesenteric LN) were PCR
positive in only one animal. These same tissues were positive for
RhCMV DNA in at least one of the p.o. inoculated animals, except
for inguinal and mesenteric LN. Other than the consistent
positive signal observed for the spleen, there was no apparent pattern
to the particular tissues or number of tissues positive for
RhCMV DNA at the different time points analyzed. The limit of
sensitivity of PCR detection of viral DNA was approximately 10 viral
genome equivalents per µg of cellular DNA, or 10 viral genome
equivalents per 3 × 105 cells (data not shown).
 |
DISCUSSION |
Experimental inoculation of rhesus macaques with RhCMV
paralleled two fundamental aspects of HCMV infection in humans: (i) limited pathogenic potential in healthy, immunocompetent hosts and (ii)
persistent gene expression in the presence of host antiviral immune
responses. The mechanisms for these two characteristic features of CMV
infection were not identified. Our observations indicated that the
course of viral infection was not a function of the route of RhCMV
inoculation and that establishment of a stable virus-host relationship
probably required many months.
Virological and host parameters of infection were similar after either
parenteral or mucosal inoculation. Infection was characterized by an
initial burst of RhCMV DNA in the plasma at 1 to 2 wpi in all
animals. RhCMV disseminated to a common, but not identical, spectrum of tissues by the earliest time point examined for each inoculation method (2 and 4 wpi for p.o. and i.v. inoculation, respectively). The tissues positive for RhCMV DNA were consistent with those identified as sites for HCMV (36), including
those, such as bone marrow, identified as possible reservoirs of latent virus (19). The early targeting of the macrophage and
endothelial cells within the spleen by RhCMV has been observed for
murine CMV (MCMV) (30, 42). PCR detection of RhCMV DNA
in plasma and tissues suggests that after inoculation there is an
initial amplification of RhCMV at the primary site of infection
followed by hematogenous spread of the virus at 1 to 2 wpi. The virus
then spread to multiple tissues by 2 to 4 wpi, the earliest time points examined for p.o. and i.v. inoculation, respectively. The observation that DNA was observed in plasma in both p.o. and i.v. inoculated animals indicates that RhCMV dissemination from the primary site of
infection to the tissues required a blood-borne intermediate step. An
alternative model might have been that direct inoculation of virus into
the circulation obviated a hematogenous phase.
Host responses to RhCMV followed similar kinetics after either p.o.
or i.v. inoculation. All animals except 29831 developed antiviral
antibodies within 2 weeks of inoculation, with increases in titers
(total and neutralizing) and avidity indices for at least 8 and 25 wpi
(for p.o. and i.v. inoculation, respectively). Antiviral immune
responses in immunocompetent animals were sufficient to prevent
RhCMV disease. Inoculation of fetal macaques or juvenile macaques
coinfected with simian immunodeficiency virus with similar titers of
RhCMV can result in a rapid, severe pathogenic outcome (reference
44 and unpublished data). The absence of both
disease and prolonged presence of DNA in plasma suggested that early
immune responses effectively restricted RhCMV sequelae. The decline
in plasma DNA levels occurred when anti-RhCMV IgG antibodies were low (or undetectable) in titer and of low avidity. This argues that IgM
and innate immune responses were important for limitation of acute
disease but were not effective for preventing viral dissemination throughout the host. The kinetics of cell-mediated antiviral immunity were not evaluated in this study. Host immune responses were
insufficient to eliminate reservoirs of persistent virus gene
expression. Prolonged (i.e., 6 months) RhCMV gene expression (IE1)
was observed in the spleens of i.v. inoculated animals that had
developed high-avidity and high-titer neutralizing antiviral
antibodies. It was not determined whether gene expression was
associated with the production of infectious virus.
An intriguing aspect of these studies was the differential localization
in the spleen of IE1-positive cells at different times following i.v.
inoculation. Assuming that the two i.v. inoculated animals examined at
each of the three time points represented a continuum of the infection
process, there was a pronounced change in the sites of IE1-expressing
cells. This shift was noted for a change from a predominantly
follicular expression pattern at 4 wpi to one of predominantly red pulp
expression at 25 wpi. The transition for the location of IE1-positive
cells has not been previously described. The localization of virally
infected cells within and around the follicles at 4 wpi in this study
was similar to that observed with mice experimentally inoculated with
MCMV (42). In that study, the authors postulated that the
pattern of MCMV-infected cells corresponded to that of marginal-zone
macrophages and dendritic cells. The morphological features of
IE1-expressing cells in the macaques were consistent with multiple cell
types, including macrophages, endothelial cells, and other cells. We colocalized IE1 expression with markers for endothelial cells in the
follicles (Fig. 3D) and tissue macrophages (Fig. 3E) in the red pulp.
However, the vast majority of IE1-expressing cells were not colabeled
with these cell markers or with those for dendritic, B, plasma, or T
cells. The identity of these IE1-expressing cells remains unknown, and
their characterization is important, since they constituted the bulk of
virus-positive cells within the spleen.
Several non-mutually exclusive theories can describe the apparent shift
in virus expression within the spleen. One is that the pattern of
IE1-positive cells represents trafficking of virus through the spleen
at different stages of infection. According to this hypothesis,
infection of follicle-associated cells during the acute phase is
necessary for subsequent infection of cells within the red pulp.
Alternatively, there may be differential susceptibility of cells within
the spleen to host immune mechanisms. The host might preferentially
eliminate virus-expressing cells within the follicle, such that
IE1-positive cells within the red pulp predominated by 25 wpi. Finally,
viral gene expression may decrease to undetectable levels in
follicle-associated cells prior to doing so in cells in the red pulp.
Such a mechanism can be considered an extension of the second
hypothesis, particularly if virus-expressing cells in the follicle are
immunologically more susceptible than those in the red pulp. The
temporal profile of RhCMV IE1-positive cells within the spleen
implies a continuous process in the establishment of a persistent infection.
In summary, conditions have been established for inoculation of healthy
rhesus macaques with RhCMV to study viral and host parameters of
infection. The results of this study and others (3, 7, 8, 22, 25,
26, 43, 44, 47) demonstrate that the nonhuman primate system is
an extremely relevant model for the study of HCMV persistence and pathogenesis.
 |
ACKNOWLEDGMENTS |
We thank Bill Britt, Robert Cardiff, Jennifer Loomis-Huff, and
Chris Miller for enlightening comments and suggestions.
This work was supported by NIH grants RO1 HL-57883 and RO1 NS-36859 (to
P.A.B.) and by the base grant to the California Regional Primate
Research Center (P51 RR-AG00169).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Center for
Comparative Medicine, University of California, Davis, CA 95616. Phone: (530) 752-6912. Fax: (530) 752-7914. E-mail:
pabarry{at}ucdavis.edu.
 |
REFERENCES |
| 1.
|
Ahn, K.,
A. Angulo,
P. Ghazal,
P. A. Peterson,
Y. Yang, and K. Fruh.
1996.
Human cytomegalovirus inhibits antigen presentation by a sequential multistep process.
Proc. Natl. Acad. Sci. USA
93:10990-10995[Abstract/Free Full Text].
|
| 2.
|
Ahn, K.,
A. Gruhler,
B. Galocha,
T. R. Jones,
E. J. Wiertz,
H. L. Ploegh,
P. A. Peterson,
Y. Yang, and K. Fruh.
1997.
The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP.
Immunity
6:613-621[Medline].
|
| 3.
|
Alcendor, D. J.,
P. A. Barry,
E. Pratt-Lowe, and P. A. Luciw.
1993.
Analysis of the rhesus cytomegalovirus immediate-early gene promoter.
Virology
194:815-821[Medline].
|
| 4.
|
Alford, C. A., and W. J. Britt.
1993.
Cytomegalovirus, p. 227-255.
In
B. Roizman, R. J. Whitley, and C. Lopez (ed.), The human herpesviruses. Raven Press, New York, N.Y.
|
| 5.
|
Andreoni, M.,
M. Faircloth,
L. Vugler, and W. J. Britt.
1989.
A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus.
J. Virol. Methods
23:157-168[Medline].
|
| 6.
|
Asher, D. M.,
J. C. J. Gibbs,
D. J. Lang, and D. C. Gadjusek.
1974.
Persistent shedding of cytomegalovirus in the urine of healthy rhesus monkeys.
Proc. Soc. Exp. Biol. Med.
145:794-801[Medline].
|
| 7.
|
Baroncelli, S.,
P. A. Barry,
J. P. Capitanio,
N. W. Lerche,
M. Otsyula, and S. P. Mendoza.
1997.
Cytomegalovirus and simian immunodeficiency virus coinfection: longitudinal study of antibody responses and disease progression.
J. Acquired Immune Defic. Syndr.
15:5-15.
|
| 8.
|
Barry, P. A.,
D. J. Alcendor,
M. D. Power,
H. Kerr, and P. A. Luciw.
1996.
Nucleotide sequence and molecular analysis of the rhesus cytomegalovirus immediate-early gene and the UL121-117 open reading frames.
Virology
215:61-72[Medline].
|
| 9.
|
Bolovan-Fritts, C. A.,
E. S. Mocarski, and J. A. Wiedeman.
1999.
Peripheral blood CD14+ cells from healthy individuals carry a circular conformation of latent cytomegalovirus genome.
Blood
93:394-398[Abstract/Free Full Text].
|
| 10.
|
Boppana, S. B., and W. J. Britt.
1995.
Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection.
J. Infect. Dis.
171:1115-1121[Medline].
|
| 10a.
| Britt, W. J., and P. Barry. Unpublished data.
|
| 11.
|
Chang, Y.-N.,
K.-T. Jeang,
T. Lietman, and G. S. Hayward.
1995.
Structural organization of the spliced immediate-early gene complex that encodes the major acidic nuclear (IE1) and transactivator (IE2) proteins of African green monkey cytomegalovirus.
J. Biomed. Sci.
2:105-130[Medline].
|
| 12.
|
Collier, A. C.,
J. D. Meyers,
L. Corey,
V. L. Murphy,
P. L. Roberts, and H. H. Handsfield.
1987.
Cytomegalovirus infection in homosexual men: relationship to sexual practices, antibodies to human immunodeficiency virus, and cell-mediated immunity.
Am. J. Med.
82:593-601[Medline].
|
| 13.
|
Dairaghi, D. J.,
D. R. Greaves, and T. J. Schall.
1998.
Abduction of chemokine elements by herpesviruses.
Semin. Virol.
8:377-385.
|
| 14.
|
Drew, L. W.,
L. Mintz,
R. C. Miner,
M. Sands, and B. Ketterer.
1981.
Prevalence of cytomegalovirus infection in homosexual men.
J. Infect. Dis.
143:188-192[Medline].
|
| 15.
|
Dworsky, M.,
M. Yow,
S. Stagno,
R. F. Pass, and C. Alford.
1983.
Cytomegalovirus infection of breast milk and transmission in infancy.
Pediatrics
72:295-299[Abstract/Free Full Text].
|
| 16.
|
Dworsky, M. E.,
K. Welch,
G. Cassady, and S. Stagno.
1983.
Occupational risk for primary cytomegalovirus infection among pediatric health-care workers.
N. Engl. J. Med.
309:950-953[Abstract].
|
| 17.
|
Fish, K. N.,
C. Söderberg-Nauclér,
L. K. Mills,
S. Stebglein, and J. A. Nelson.
1998.
Human cytomegalovirus persistently infects aortic endothelial cells.
J. Virol.
72:5661-5668[Abstract/Free Full Text].
|
| 18.
|
Grefte, A.,
M. C. Harmsen,
M. van der Giessen,
S. Knollema,
W. J. van Son, and T. H. The.
1994.
The presence of human cytomegalovirus (HCMV) immediate early mRNA but not ppUL83 (lower matrix protein pp65) mRNA in polymorphonuclear and mononuclear leukocytes during active HCMV infection.
J. Gen. Virol.
74:1989-1998[Abstract/Free Full Text].
|
| 19.
|
Hahn, G.,
R. Jores, and E. S. Mocarski.
1998.
Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells.
Proc. Natl. Acad. Sci. USA
95:3937-3942[Abstract/Free Full Text].
|
| 20.
|
Jones, T. R., and L. Sun.
1997.
Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains.
J. Virol.
71:2970-2979[Abstract].
|
| 21.
|
Jones, T. R.,
E. J. Wiertz,
L. Sun,
K. N. Fish,
J. A. Nelson, and H. L. Ploegh.
1996.
Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains.
Proc. Natl. Acad. Sci. USA
93:11327-11333[Abstract/Free Full Text].
|
| 22.
|
Kaur, A.,
M. D. Daniel,
D. Hempel,
D. Lee-Parritz,
M. S. Hirsch, and R. P. Johnson.
1996.
Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected macaques.
J. Virol.
70:7725-7733[Abstract].
|
| 23.
|
Kondo, K.,
H. Kaneshima, and E. S. Mocarski.
1994.
Human cytomegalovirus latent infection of granulocyte-macrophage progenitors.
Proc. Natl. Acad. Sci. USA
91:11879-11883[Abstract/Free Full Text].
|
| 24.
|
Kondo, K.,
J. Xu, and E. S. Mocarski.
1996.
Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals.
Proc. Natl. Acad. Sci. USA
93:11137-11142[Abstract/Free Full Text].
|
| 25.
|
Kravitz, R. H.,
K. S. Sciabica,
K. Cho,
P. A. Luciw, and P. A. Barry.
1997.
Cloning and characterization of the rhesus cytomegalovirus glycoprotein B.
J. Gen. Virol.
78:2009-2013[Abstract].
|
| 26.
|
Kropff, B., and M. Mach.
1997.
Identification of the gene coding for rhesus cytomegalovirus glycoprotein B and immunological analysis of the protein.
J. Gen. Virol.
78:1999-2007[Abstract].
|
| 27.
|
London, W. T.,
A. J. Martinez,
S. A. Houff,
W. C. Wallen,
B. L. Curfman,
R. G. Traub, and J. L. Sever.
1986.
Experimental congenital disease with simian cytomegalovirus in rhesus monkeys.
Teratology
33:323-331[Medline].
|
| 28.
|
Machold, R. P.,
E. J. Wiertz,
T. R. Jones, and H. L. Ploegh.
1997.
The HCMV gene products US11 and US2 differ in their ability to attack allelic forms of murine major histocompatibility complex (MHC) class I heavy chains.
J. Exp. Med.
185:363-366[Abstract/Free Full Text].
|
| 29.
|
McVoy, M. A., and S. P. Adler.
1989.
Immunologic evidence for frequent age-related cytomegalovirus reactivation in seropositive immunocompetent individuals.
J. Infect. Dis.
160:1-10[Medline].
|
| 30.
|
Mercer, J. A.,
C. A. Wiley, and D. H. Spector.
1988.
Pathogenesis of murine cytomegalovirus infection: identification of infected cells in the spleen during acute and latent infections.
J. Virol.
62:987-997[Abstract/Free Full Text].
|
| 31.
|
Middeldorp, J. M.,
J. Jongsma,
A. ter Haar,
J. Schirm, and T. H. The.
1984.
Detection of immunoglobulin M and G antibodies against cytomegalovirus early and late antigens by enzyme-linked immunosorbent assay.
J. Clin. Microbiol.
20:763-771[Abstract/Free Full Text].
|
| 32.
|
Mocarski, E. S. J.
1993.
Cytomegalovirus biology and replication, p. 173-226.
In
B. Roizman, R. J. Whitley, and C. Lopez (ed.), The human herpesviruses. Raven Press, New York, N.Y.
|
| 33.
|
Neote, K.,
D. DiGregorio,
J. Y. Mak,
R. Horuk, and T. J. Schall.
1993.
Molecular cloning, functional expression, and signaling characteristics of a CC chemokine receptor.
Cell
72:415-425[Medline].
|
| 34.
|
Pass, R. F.,
S. Stagno,
M. E. Dworsky,
R. J. Smith, and C. A. Alford.
1982.
Excretion of cytomegalovirus in mothers: observations after delivery of congenitally infected and normal infants.
J. Infect. Dis.
146:1-6[Medline].
|
| 35.
|
Pinkus, G. S.,
J. L. Pinkus,
E. Langhoff,
F. Matsumura,
S. Yamashiro,
G. Mosialos, and J. W. Said.
1997.
Fascin, a sensitive new marker for Reed-Sternberg cells of Hodgkin's disease.
Am. J. Pathol.
150:543-562[Abstract].
|
| 36.
|
Plachter, B.,
C. Sinzger, and G. Jahn.
1996.
Cell types involved in replication and distribution of human cytomegalovirus.
Adv. Virus Res.
46:195-261[Medline].
|
| 37.
|
Reyburn, H. T.,
O. Mandelboim,
M. Vales-Gomez,
D. M. Davis,
L. Pazmany, and J. L. Strominger.
1997.
The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells.
Nature
386:514-517[Medline].
|
| 38.
|
Reynolds, D. W.,
S. Stagno,
T. S. Hosty,
M. Tiller, and C. A. Alford, Jr.
1973.
Maternal cytomegalovirus excretion and perinatal infection.
N. Engl. J. Med.
289:1-5.
|
| 39.
|
Rice, G. P. A.,
R. D. Schrier, and M. B. A. Oldstone.
1984.
Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate early gene products.
Proc. Natl. Acad. Sci. USA
81:6134-6138[Abstract/Free Full Text].
|
| 40.
|
Söderberg-Nauclér, C.,
K. N. Fish, and J. A. Nelson.
1997.
Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors.
Cell
91:119-126[Medline].
|
| 41.
|
Stagno, S.,
D. W. Reynolds,
R. F. Pass, and C. A. Alford.
1980.
Breast milk and the risk of cytomegalovirus infection.
N. Engl. J. Med.
302:1073-1076[Medline].
|
| 42.
|
Stoddart, C. A.,
R. D. Cardin,
J. M. Boname,
W. C. Manning,
G. B. Abenes, and E. S. Mocarski.
1994.
Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus.
J. Virol.
68:6243-6253[Abstract/Free Full Text].
|
| 43.
|
Swanson, R.,
E. Bergquam, and S. W. Wong.
1998.
Characterization of rhesus cytomegalovirus genes associated with anti-viral susceptibility.
Virology
240:338-348[Medline].
|
| 44.
|
Tarantal, A. F.,
S. Salamat,
W. J. Britt,
P. A. Luciw,
A. G. Hendrickx, and P. A. Barry.
1998.
Neuropathogenesis induced by rhesus cytomegalovirus in fetal rhesus monkeys (Macaca mulatta).
J. Infect. Dis.
177:446-450[Medline].
|
| 45.
|
Taylor-Weideman, J.,
J. G. P. Sissons,
L. K. Borysiewicz, and J. H. Sinclair.
1991.
Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells.
J. Gen. Virol.
72:2059-2064[Abstract/Free Full Text].
|
| 46.
|
Tehranian, A.,
D. W. Morris,
B. H. Min,
D. J. Bird,
R. D. Cardiff, and P. A. Barry.
1996.
Neoplastic transformation of prostatic and urogenital epithelium by the polyoma virus middle T gene.
Am. J. Pathol.
149:1177-1191[Abstract].
|
| 47.
|
Vogel, P.,
B. J. Weigler,
H. Kerr,
A. Hendrickx, and P. A. Barry.
1994.
Seroepidemiologic studies of cytomegalovirus infection in a breeding population of rhesus macaques.
Lab. Anim. Sci.
44:25-30[Medline].
|
| 48.
|
Wiertz, E. J.,
T. R. Jones,
L. Sun,
M. Bogyo,
H. J. Geuze, and H. L. Ploegh.
1996.
The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol.
Cell
84:769-779[Medline].
|
| 49.
|
Zhuravskaya, T.,
J. P. Maciejewski,
D. M. Netski,
E. Bruening,
F. R. Mackintosh, and S. St. Jeor.
1997.
Spread of human cytomegalovirus (HCMV) after infection of human hematopoietic progenitor cells: model of HCMV latency.
Blood
90:2482-2491[Abstract/Free Full Text].
|
Journal of Virology, November 1999, p. 9576-9583, Vol. 73, No. 11
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lilja, A. E., Chang, W. L. W., Barry, P. A., Becerra, S. P., Shenk, T. E.
(2008). Functional Genetic Analysis of Rhesus Cytomegalovirus: Rh01 Is an Epithelial Cell Tropism Factor. J. Virol.
82: 2170-2181
[Abstract]
[Full Text]
-
Price, D. A., Bitmansour, A. D., Edgar, J. B., Walker, J. M., Axthelm, M. K., Douek, D. C., Picker, L. J.
(2008). Induction and Evolution of Cytomegalovirus-Specific CD4+ T Cell Clonotypes in Rhesus Macaques. J. Immunol.
180: 269-280
[Abstract]
[Full Text]
-
Yue, Y., Kaur, A., Eberhardt, M. K., Kassis, N., Zhou, S. S., Tarantal, A. F., Barry, P. A.
(2007). Immunogenicity and Protective Efficacy of DNA Vaccines Expressing Rhesus Cytomegalovirus Glycoprotein B, Phosphoprotein 65-2, and Viral Interleukin-10 in Rhesus Macaques. J. Virol.
81: 1095-1109
[Abstract]
[Full Text]
-
Yue, Y., Kaur, A., Zhou, S. S., Barry, P. A.
(2006). Characterization and immunological analysis of the rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower matrix phosphoprotein (pp65).. J. Gen. Virol.
87: 777-787
[Abstract]
[Full Text]
-
Rivailler, P., Kaur, A., Johnson, R. P., Wang, F.
(2006). Genomic sequence of rhesus cytomegalovirus 180.92: insights into the coding potential of rhesus cytomegalovirus.. J. Virol.
80: 4179-4182
[Abstract]
[Full Text]
-
Khan, I. H., Mendoza, S., Yee, J., Deane, M., Venkateswaran, K., Zhou, S. S., Barry, P. A., Lerche, N. W., Luciw, P. A.
(2006). Simultaneous Detection of Antibodies to Six Nonhuman-Primate Viruses by Multiplex Microbead Immunoassay. CVI
13: 45-52
[Abstract]
[Full Text]
-
DeFilippis, V., Fruh, K.
(2005). Rhesus Cytomegalovirus Particles Prevent Activation of Interferon Regulatory Factor 3. J. Virol.
79: 6419-6431
[Abstract]
[Full Text]
-
Abel, K., Wang, Y., Fritts, L., Sanchez, E., Chung, E., Fitzgerald-Bocarsly, P., Krieg, A. M., Miller, C. J.
(2005). Deoxycytidyl-Deoxyguanosine Oligonucleotide Classes A, B, and C Induce Distinct Cytokine Gene Expression Patterns in Rhesus Monkey Peripheral Blood Mononuclear Cells and Distinct Alpha Interferon Responses in TLR9-Expressing Rhesus Monkey Plasmacytoid Dendritic Cells. CVI
12: 606-621
[Abstract]
[Full Text]
-
Carlson, J. R., Chang, W. L. W., Zhou, S. S., Tarantal, A. F., Barry, P. A.
(2005). Rhesus brain microvascular endothelial cells are permissive for rhesus cytomegalovirus infection. J. Gen. Virol.
86: 545-549
[Abstract]
[Full Text]
-
Rue, C. A., Jarvis, M. A., Knoche, A. J., Meyers, H. L., DeFilippis, V. R., Hansen, S. G., Wagner, M., Fruh, K., Anders, D. G., Wong, S. W., Barry, P. A., Nelson, J. A.
(2004). A Cyclooxygenase-2 Homologue Encoded by Rhesus Cytomegalovirus Is a Determinant for Endothelial Cell Tropism. J. Virol.
78: 12529-12536
[Abstract]
[Full Text]
-
North, T. W., Sequar, G., Townsend, L. B., Drach, J. C., Barry, P. A.
(2004). Rhesus Cytomegalovirus Is Similar to Human Cytomegalovirus in Susceptibility to Benzimidazole Nucleosides. Antimicrob. Agents Chemother.
48: 2760-2765
[Abstract]
[Full Text]
-
Yue, Y., Zhou, S. S., Barry, P. A.
(2003). Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques. J. Gen. Virol.
84: 3371-3379
[Abstract]
[Full Text]
-
Penfold, M. E. T., Schmidt, T. L., Dairaghi, D. J., Barry, P. A., Schall, T. J.
(2003). Characterization of the Rhesus Cytomegalovirus US28 Locus. J. Virol.
77: 10404-10413
[Abstract]
[Full Text]
-
Chang, W. L. W., Barry, P. A.
(2003). Cloning of the Full-Length Rhesus Cytomegalovirus Genome as an Infectious and Self-Excisable Bacterial Artificial Chromosome for Analysis of Viral Pathogenesis. J. Virol.
77: 5073-5083
[Abstract]
[Full Text]
-
Huff, J. L., Eberle, R., Capitanio, J., Zhou, S. S., Barry, P. A.
(2003). Differential detection of B virus and rhesus cytomegalovirus in rhesus macaques. J. Gen. Virol.
84: 83-92
[Abstract]
[Full Text]
-
Chang, W. L. W., Tarantal, A. F., Zhou, S. S., Borowsky, A. D., Barry, P. A.
(2002). A Recombinant Rhesus Cytomegalovirus Expressing Enhanced Green Fluorescent Protein Retains the Wild-Type Phenotype and Pathogenicity in Fetal Macaques. J. Virol.
76: 9493-9504
[Abstract]
[Full Text]
-
Sequar, G., Britt, W. J., Lakeman, F. D., Lockridge, K. M., Tarara, R. P., Canfield, D. R., Zhou, S.-S., Gardner, M. B., Barry, P. A.
(2002). Experimental Coinfection of Rhesus Macaques with Rhesus Cytomegalovirus and Simian Immunodeficiency Virus: Pathogenesis. J. Virol.
76: 7661-7671
[Abstract]
[Full Text]